Resverlogix: The Future of Drug Development

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-bas …

October 4, 2021
Request Investor InfoRequest Investor Info
Resverlogix

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.

Investing
stock market

You might also like

Chilean Cobalt: Why Is Securing Critical Mineral Supply Becoming a Strategic Priority?
Metals & Mining
September 9, 2026

Chilean Cobalt: Why Is Securing Critical Mineral Supply Becoming a Strategic Priority?

Chilean Cobalt is advancing projects focused on supplying two of the world's most strategic critical minerals: cobalt and copper.

This is some text inside of a div block.
Contango Silver and Gold: Advancing Toward Near-Term Precious Metals Production
Metals & Mining
September 8, 2026

Contango Silver and Gold: Advancing Toward Near-Term Precious Metals Production

This is some text inside of a div block.
HHIC - Harvest ETFs: Built for Income, Designed for Canada
ETFs
September 4, 2026

HHIC - Harvest ETFs: Built for Income, Designed for Canada

Harvest ETFs’ HHIC offers exposure to Canada’s leading businesses with a focus on high monthly income and consistent performance.

This is some text inside of a div block.
Subscribe and receive the investor Info